N
Naftidrofuryl (Praxilene),
402
Named patient, unlicensed drugs,
66
Narcotic analgesics, monoamine oxidase inhibitor interactions,
321
Narrow-spectrum penicillins,
175
Natalizumab (Tysabri),
368
National Institute for Health and Clinical Excellence (NICE)
Natural antimicrobial resistance,
169
Natural products, drug discovery and development,
32
Natural units, benefits,
59
Nausea and vomiting,
533–534
quinupristin-dalfopristin (Synercid),
186
Necrotising fasciitis,
192
Negative reactors, placebos,
18
Negligence
drug-induced injury,
13–14
Neisseria meningitidis meningitis,
197,
198
Neoadjuvant therapy, neoplastic disease,
509–510
Neomycin,
181
hepatic encephalopathy,
551
Neonatal septicaemia,
191
Neoplastic disease,
509–523
bronchogenic carcinoma,
151
oral combined contraceptive,
607
signal transduction inhibitors,
521
Neostigmine,
303
anticholinesterase effects,
375
myasthenia gravis treatment,
377
Nephrogenic diabetes insipidus,
457
Neural mechanisms, drugs of abuse,
139,
140f
Neuraminidase inhibitors,
220 see also specific drugs
Neuroleptic malignant syndrome,
328
Neurological disorders,
349–369 see also specific diseases/disorders
Neuromuscular blocking drugs,
302–303
Neuromuscular junctions, cholinergic drugs,
373,
374
Neuromuscular transmission disorders,
377–379
drug-induced,
378–379 see also specific diseases/disorders
Neurone-blocking adrenoceptor-blocking drugs,
409
Neuropsychiatric adverse effects, mefloquine,
233
Neutropenia
penicillin adverse effects,
174–175
Neutrophils, inflammation,
241
Niacin (nicotinic acid: vitamin B
7),
616–617
Nicotine-replacement therapy,
152
Nicotinic acid
hyperlipidaemia treatment,
450
Nicoumalone (acenocoumarol),
488
Nigrostriatal system, antipsychotic drugs,
323
NMDA receptors (
N-methyl-d-aspartate),
279
N-of-1 clinical trials,
47–48
No-fault compensation schemes,
12
No-fault liability,
13–14
Nomenclature of drugs,
69–71
non-proprietary name,
69,
70
non-proprietary (brand) name,
70–71
proprietary (brand) name,
70,
71
Non-alcohol related fatty liver disease,
553
Non-allergic reactions, asthma,
473
Non-benzodiazepine hypnotic drugs,
341
Non-calcareous stones, nephrolithiasis,
463
Non-coronary thrombolysis, thrombolytic drugs,
491–492
Non-emulsifying ointments,
262
Non-ergot dopamine agonists,
363–364
Non-gonococcal urethritis,
201
Non-inferiority, clinical trials,
46
Non-motor symptoms, Parkinson's disease,
361
Non-nucleoside reverse transcriptase inhibitors,
219
Non-overlapping toxicity, cytotoxic drugs,
516
Non-proprietary (brand) name,
69,
70–71
Non-specific vaccines,
518
Non-steroidal anti-inflammatory drugs (NSAIDs),
243–246,
281–282
cardiovascular effects,
243
topical applications,
262
use limitations,
533 see also specific drugs
Non-urticarial rashes,
116
Noradrenaline,
387–388
antidepressant drug mode of action,
313
Norephedrine (phenylpropanolamine),
389
Norethisterone enanthate,
609
Normal commensals, pneumonias,
194
Novel antidepressant drugs,
312,
312t
Novelty, drug discovery and development,
30
Novel uses, drug discovery and development,
33
NovoRapid (Insulin Aspart),
575t
Nucleic acid metabolism,
164
Nucleic acid synthesis, antibacterial drugs,
173–174,
187
Nucleoside analogues,
512t
Nucleoside and nucleotide reverse transcriptase inhibitors (NNRTIs),
217–218
Nucleotide analogs, hepatitis B virus,
553
Nutrizyme (pancreatin/Cotazym),
555